Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.55
MASI's Cash to Debt is ranked lower than
74% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MASI: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
MASI' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 422.97 Max: N/A
Current: 0.55
Equity to Asset 0.47
MASI's Equity to Asset is ranked lower than
75% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MASI: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
MASI' s Equity to Asset Range Over the Past 10 Years
Min: -1.01  Med: 0.74 Max: 0.81
Current: 0.47
-1.01
0.81
F-Score: 7
Z-Score: 6.34
M-Score: -2.50
WACC vs ROIC
5.51%
25.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.57
MASI's Operating margin (%) is ranked higher than
87% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. MASI: 18.57 )
Ranked among companies with meaningful Operating margin (%) only.
MASI' s Operating margin (%) Range Over the Past 10 Years
Min: 8.35  Med: 21.48 Max: 137.71
Current: 18.57
8.35
137.71
Net-margin (%) 12.87
MASI's Net-margin (%) is ranked higher than
82% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MASI: 12.87 )
Ranked among companies with meaningful Net-margin (%) only.
MASI' s Net-margin (%) Range Over the Past 10 Years
Min: 10.4  Med: 14.88 Max: 81.05
Current: 12.87
10.4
81.05
ROE (%) 27.44
MASI's ROE (%) is ranked higher than
96% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MASI: 27.44 )
Ranked among companies with meaningful ROE (%) only.
MASI' s ROE (%) Range Over the Past 10 Years
Min: 17.28  Med: 22.48 Max: 28.48
Current: 27.44
17.28
28.48
ROA (%) 14.19
MASI's ROA (%) is ranked higher than
93% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. MASI: 14.19 )
Ranked among companies with meaningful ROA (%) only.
MASI' s ROA (%) Range Over the Past 10 Years
Min: 12.07  Med: 17.83 Max: 140.05
Current: 14.19
12.07
140.05
ROC (Joel Greenblatt) (%) 64.96
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. MASI: 64.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MASI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.38  Med: 141.81 Max: 1390.13
Current: 64.96
52.38
1390.13
Revenue Growth (3Y)(%) 13.60
MASI's Revenue Growth (3Y)(%) is ranked higher than
81% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MASI: 13.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MASI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.3  Med: 12.95 Max: 30.3
Current: 13.6
-19.3
30.3
EBITDA Growth (3Y)(%) 10.70
MASI's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. MASI: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MASI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.50 Max: 259.6
Current: 10.7
0
259.6
EPS Growth (3Y)(%) 7.60
MASI's EPS Growth (3Y)(%) is ranked higher than
57% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. MASI: 7.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MASI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.7  Med: 7.60 Max: 46.5
Current: 7.6
-33.7
46.5
» MASI's 10-Y Financials

Financials (Next Earnings Date: 2016-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MASI Guru Trades in Q1 2015

Joel Greenblatt 42,408 sh (New)
Chuck Royce 441,000 sh (New)
Jim Simons 142,700 sh (+42.56%)
Mario Gabelli 134,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham 52,900 sh (-3.11%)
» More
Q2 2015

MASI Guru Trades in Q2 2015

Jim Simons 155,600 sh (+9.04%)
Mario Gabelli 134,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 321,000 sh (-27.21%)
Jeremy Grantham 35,400 sh (-33.08%)
» More
Q3 2015

MASI Guru Trades in Q3 2015

Paul Tudor Jones 8,800 sh (New)
Jeremy Grantham 35,400 sh (unchged)
Mario Gabelli 134,000 sh (unchged)
Chuck Royce 251,000 sh (-21.81%)
Jim Simons 113,200 sh (-27.25%)
» More
Q4 2015

MASI Guru Trades in Q4 2015

John Hussman 125,000 sh (New)
Jim Simons 222,400 sh (+96.47%)
Mario Gabelli 132,000 sh (-1.49%)
Jeremy Grantham 31,100 sh (-12.15%)
Chuck Royce 182,000 sh (-27.49%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.65
MASI's P/E(ttm) is ranked higher than
61% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. MASI: 23.65 )
Ranked among companies with meaningful P/E(ttm) only.
MASI' s P/E(ttm) Range Over the Past 10 Years
Min: 16.96  Med: 25.06 Max: 91.05
Current: 23.65
16.96
91.05
Forward P/E 18.55
MASI's Forward P/E is ranked lower than
54% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. MASI: 18.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.65
MASI's PE(NRI) is ranked higher than
58% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 27.40 vs. MASI: 23.65 )
Ranked among companies with meaningful PE(NRI) only.
MASI' s PE(NRI) Range Over the Past 10 Years
Min: 17.04  Med: 25.15 Max: 66.16
Current: 23.65
17.04
66.16
P/B 6.65
MASI's P/B is ranked lower than
100% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MASI: 6.65 )
Ranked among companies with meaningful P/B only.
MASI' s P/B Range Over the Past 10 Years
Min: 3.54  Med: 5.69 Max: 15.2
Current: 6.65
3.54
15.2
P/S 3.05
MASI's P/S is ranked lower than
64% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. MASI: 3.05 )
Ranked among companies with meaningful P/S only.
MASI' s P/S Range Over the Past 10 Years
Min: 1.77  Med: 3.24 Max: 9.79
Current: 3.05
1.77
9.79
PFCF 64.38
MASI's PFCF is ranked lower than
81% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 34.47 vs. MASI: 64.38 )
Ranked among companies with meaningful PFCF only.
MASI' s PFCF Range Over the Past 10 Years
Min: 14.5  Med: 32.14 Max: 2642
Current: 64.38
14.5
2642
POCF 23.14
MASI's POCF is ranked lower than
59% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. MASI: 23.14 )
Ranked among companies with meaningful POCF only.
MASI' s POCF Range Over the Past 10 Years
Min: 13.18  Med: 23.32 Max: 51.16
Current: 23.14
13.18
51.16
EV-to-EBIT 16.03
MASI's EV-to-EBIT is ranked higher than
70% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. MASI: 16.03 )
Ranked among companies with meaningful EV-to-EBIT only.
MASI' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.1  Med: 16.10 Max: 111.2
Current: 16.03
6.1
111.2
EV-to-EBITDA 14.31
MASI's EV-to-EBITDA is ranked higher than
63% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. MASI: 14.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
MASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 14.65 Max: 103.4
Current: 14.31
5.7
103.4
PEG 6.03
MASI's PEG is ranked lower than
71% of the 68 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. MASI: 6.03 )
Ranked among companies with meaningful PEG only.
MASI' s PEG Range Over the Past 10 Years
Min: 4.19  Med: 13.76 Max: 411.6
Current: 6.03
4.19
411.6
Shiller P/E 27.51
MASI's Shiller P/E is ranked higher than
60% of the 72 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. MASI: 27.51 )
Ranked among companies with meaningful Shiller P/E only.
MASI' s Shiller P/E Range Over the Past 10 Years
Min: 17.49  Med: 28.20 Max: 33.69
Current: 27.51
17.49
33.69
Current Ratio 2.66
MASI's Current Ratio is ranked higher than
50% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. MASI: 2.66 )
Ranked among companies with meaningful Current Ratio only.
MASI' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.97 Max: 4.87
Current: 2.66
1.25
4.87
Quick Ratio 2.01
MASI's Quick Ratio is ranked higher than
51% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MASI: 2.01 )
Ranked among companies with meaningful Quick Ratio only.
MASI' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.46 Max: 4.34
Current: 2.01
0.99
4.34
Days Inventory 122.25
MASI's Days Inventory is ranked higher than
57% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. MASI: 122.25 )
Ranked among companies with meaningful Days Inventory only.
MASI' s Days Inventory Range Over the Past 10 Years
Min: 55.77  Med: 102.51 Max: 117.9
Current: 122.25
55.77
117.9
Days Sales Outstanding 44.10
MASI's Days Sales Outstanding is ranked higher than
82% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. MASI: 44.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
MASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 44.47 Max: 52.39
Current: 44.1
36.51
52.39
Days Payable 50.61
MASI's Days Payable is ranked lower than
57% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. MASI: 50.61 )
Ranked among companies with meaningful Days Payable only.
MASI' s Days Payable Range Over the Past 10 Years
Min: 54.25  Med: 66.20 Max: 78.42
Current: 50.61
54.25
78.42

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.07
MASI's Price/Tangible Book is ranked lower than
66% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 4.04 vs. MASI: 8.07 )
Ranked among companies with meaningful Price/Tangible Book only.
MASI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.11  Med: 6.28 Max: 15.3
Current: 8.07
4.11
15.3
Price/Projected FCF 2.36
MASI's Price/Projected FCF is ranked lower than
64% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. MASI: 2.36 )
Ranked among companies with meaningful Price/Projected FCF only.
MASI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.22  Med: 1.93 Max: 3.93
Current: 2.36
1.22
3.93
Price/Median PS Value 0.94
MASI's Price/Median PS Value is ranked higher than
53% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MASI: 0.94 )
Ranked among companies with meaningful Price/Median PS Value only.
MASI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 0.98 Max: 2.74
Current: 0.94
0.63
2.74
Price/Peter Lynch Fair Value 4.22
MASI's Price/Peter Lynch Fair Value is ranked lower than
79% of the 73 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. MASI: 4.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MASI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.93  Med: 1.21 Max: 4.59
Current: 4.22
0.93
4.59
Price/Graham Number 2.91
MASI's Price/Graham Number is ranked lower than
53% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. MASI: 2.91 )
Ranked among companies with meaningful Price/Graham Number only.
MASI' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 2.78 Max: 6.22
Current: 2.91
1.8
6.22
Earnings Yield (Greenblatt) (%) 6.27
MASI's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. MASI: 6.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MASI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.9  Med: 6.20 Max: 16.4
Current: 6.27
0.9
16.4
Forward Rate of Return (Yacktman) (%) 7.60
MASI's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 5.28 vs. MASI: 7.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MASI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.3  Med: 5.00 Max: 14.1
Current: 7.6
-2.3
14.1

More Statistics

Revenue(Mil) $625
EPS $ 1.49
Beta0.51
Short Percentage of Float5.15%
52-Week Range $26.81 - 46.00
Shares Outstanding(Mil)50.29

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 627 670 715
EPS($) 1.41 1.69 1.91
EPS without NRI($) 1.41 1.69 1.91

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:3M4.Germany,
Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. Its core business is measure through motion and low perfusion arterial blood oxygen saturation and pulse rate monitoring, known as Masimo SET pulse oximetry, but our product offerings have expanded significantly over the years to also include noninvasive blood constituent, brain and breath monitoring, including rainbow Pulse CO-Oximetry, brain function electroencephalogram (EEG) monitoring, respiration rate, capnography and anesthetic agent monitoring. In addition, they have developed the Root patient monitoring and connectivity platform and Patient SafetyNet remote patient surveillance monitoring system. They provide their products directly and through distributors and OEM partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. The Company sell their products to end-users through its direct sales force and certain distributors, as well as its OEM partners, for incorporation into their products. They also offer a patient surveillance or remote monitoring and clinician notification solution called Patient SafetyNet, which includes Masimo SET or rainbow SET platform measurements at the patient's bedside along with a central assignment station and wired or wireless server. In October 2012, they received both FDA clearance for uSpO2, a universal "Board-in-Cable" pulse oximetry solution, enabling easier and faster integration for OEM partners due to the ability to integrate Masimo SET through software only. The Company acquired Spire Semiconductor, LLC, a maker of advanced light emitting diode and other advanced component-level technologies. Masimo Semiconductor, Inc. (Masimo Semiconductor), its wholly owned subsidiary, operates this business and specializes in wafer epitaxy, foundry services, and device fabrication for biomedical, telecommunications, consumer products and other markets. The Company offer Masimo SET and rainbow SET through its OEMs for integration in their products and through its own end-user products, including the Root, Radical-7, Rad-87, Rad-57, Pronto-7, Pronto, Rad-8, Rad-5 and Rad-5v. The Company has 674 issued and pending patents worldwide. They have licensed from Cercacor Laboratories, Inc. (Cercacor), the right to OEM selected rainbow technology and to incorporate selected rainbow technology into their products intended to be used by professional caregivers, including, but not limited to, hospital caregivers and alternate care facility caregivers. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotio
» More Articles for MASI

Headlines

Articles On GuruFocus.com
BTIM Corp's Top Buys in Q2 2015 Jul 20 2015 
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 05 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 
Masimo Corp. Reports Operating Results (10-Q) Nov 03 2010 
Masimo Corp. Reports Operating Results (10-Q) Aug 04 2010 

More From Other Websites
8:07 am Masimo announces that co's rainbow Acoustic Monitoring was associated with fewer alarm... Feb 13 2016
Masimo’s rainbow® Acoustic Monitoring (RAM™) was Associated with Fewer Alarm Events During... Feb 12 2016
In New Clinical Study Masimo’s Oxygen Reserve Index Helps Clinicians Detect Impending Desaturation... Feb 04 2016
MASIMO CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 01 2016
Masimo to Report Fourth Quarter 2015 Financial Results after Market Close on Tuesday, February 23 Jan 29 2016
Masimo to Report Fourth Quarter 2015 Financial Results after Market Close on Tuesday, February 23 Jan 29 2016
New Study Shows Utility of Masimo rainbow Acoustic Monitoring™ Jan 21 2016
New Study Shows Utility of Masimo rainbow Acoustic Monitoring™ Jan 21 2016
Dr. Steven Barker Awarded the Society for Technology in Anesthesia’s J.S. Gravenstein Award for... Jan 19 2016
Masimo's Patient SafetyNet & Radius-7 Demand on the Rise Jan 15 2016
North Carolina’s Appalachian Regional Healthcare System Selects Patient SafetyNet™ and... Jan 13 2016
MASIMO CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 12 2016
Masimo to Debut Respiration Rate in MightySat™ at Consumer Electronics Show – First Fingertip... Jan 06 2016
Masimo to Debut Respiration Rate in MightySat™ at Consumer Electronics Show – First Fingertip... Jan 06 2016
Masimo downgraded by Raymond James Jan 06 2016
Masimo Corp. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
Masimo to Present at 34th Annual J.P. Morgan Healthcare Conference Dec 29 2015
Masimo to Present at 34th Annual J.P. Morgan Healthcare Conference Dec 29 2015
Masimo Corp. breached its 50 day moving average in a Bullish Manner : December 25, 2015 Dec 25 2015
Masimo Pledges to Increase Investment in Research & Development and Infrastructure, in Response to... Dec 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK